| 000 | 01724 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513100400.0 | ||
| 264 | 0 | _c19961018 | |
| 008 | 199610s 0 0 eng d | ||
| 022 | _a0735-1097 | ||
| 024 | 7 |
_a10.1016/0735-1097(96)00156-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStevens, S K | |
| 245 | 0 | 0 |
_aEffects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. _h[electronic resource] |
| 260 |
_bJournal of the American College of Cardiology _cAug 1996 |
||
| 300 |
_a418-22 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCardiac Pacing, Artificial |
| 650 | 0 | 4 | _aDefibrillators, Implantable |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPropafenone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aTachycardia, Ventricular _xtherapy |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVentricular Fibrillation _xtherapy |
| 700 | 1 | _aHaffajee, C I | |
| 700 | 1 | _aNaccarelli, G V | |
| 700 | 1 | _aSchwartz, K M | |
| 700 | 1 | _aLuceri, R M | |
| 700 | 1 | _aPacker, D L | |
| 700 | 1 | _aRubin, A M | |
| 700 | 1 | _aKowey, P R | |
| 773 | 0 |
_tJournal of the American College of Cardiology _gvol. 28 _gno. 2 _gp. 418-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0735-1097(96)00156-8 _zAvailable from publisher's website |
| 999 |
_c8796410 _d8796410 |
||